Section Arrow
Quote
PIRS.NASDAQ
- Pieris Pharmaceuticals
(Financial Status)
Quotes are at least 15-min delayed:2024/04/23 15:34 EDT
Last
 12.198
+0.51 (+4.36%)
Day High 
12.93 
Prev. Close
11.688 
1-M High
0.2 
Volume 
110.32K 
Bid
12.05
Ask
12.25
Day Low
11.155 
Open
11.42 
1-M Low
0.138 
Market Cap 
14.45M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 0.16 
20-SMA 0.17 
50-SMA 0.17 
52-W High 1.01 
52-W Low 0.1361 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.34/-1.16
Enterprise Value
26.70M
Balance Sheet
Book Value Per Share
0.27
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
42.81M
Operating Revenue Per Share
0.34
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8722+0.0294+3.49%-- 
JAGXJaguar Health0.1676-0.0123-6.84%-- 
IBRXImmunityBio5.6179+0.6779+13.72%-- 
PALIPalisade Bio5.98+1.05+21.30%1.03PE
NKGNNKGen Biotech1.87+0.4+27.21%-- 
Quotes are at least 15-min delayed：2024/04/23 15:34 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.